Boston Life Sciences to Hold Conference Call On January 7, 2003; Company Will Provide Quarterly Update On Its Activities.

Business Editors & Health/Medical Writers

BOSTON--(BUSINESS WIRE)--Jan. 2, 2003

Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that it will hold an investor's conference call on January 7, 2003 at 11 a.m. EDT.

The call will be moderated by Dr. Robert Rosenthal, the Company's President and Chief Operating Officer. Dr. Rosenthal will provide an update on the Company's goals and objectives for 2003, the Company's current financial position, and other related matters. Following his report, there will be a question and answer session.

To participate in the conference call, please dial [phone] within the U.S. and Canada, or for International callers [phone]. All participants must enter the following passcode to join in the call: 00653. The conference call will be recorded and may be heard on January 7, 2003 after 12p.m. EDT, by dialing [phone] within the U.S. and Canada, or International callers may dial [phone] and must enter the following passcode: 01457. The audio recording of the call will be available through January 10, 2003 until 11:59pm.

Boston Life Sciences, Inc. (BLSI) is a development stage biotechnology company engaged in the research and development of novel therapeutic and diagnostic solutions for central nervous system diseases (CNS) and cancer. BLSI's products in development include: ALTROPANE(TM) and FLUORATEC(TM) radioimaging agents for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.